Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.

Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM.

J Immunol. 2006 Jul 1;177(1):383-94.


Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD.

J Immunol. 2001 Aug 1;167(3):1490-9.


Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.

Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM.

J Immunol. 2001 Nov 15;167(10):5758-66.


Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.

Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.

J Biol Chem. 2010 Aug 27;285(35):27251-8. doi: 10.1074/jbc.M110.106617. Epub 2010 Jun 17.


The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).

Hannan JP.

Curr Protein Pept Sci. 2016;17(5):463-87. Review.


Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.

Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM.

Biochemistry. 2001 May 22;40(20):5931-41.


Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.

Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.

J Biol Chem. 2009 Apr 3;284(14):9513-20. doi: 10.1074/jbc.M808404200. Epub 2009 Jan 21.


Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).

Young KA, Chen XS, Holers VM, Hannan JP.

J Biol Chem. 2007 Dec 14;282(50):36614-25. Epub 2007 Oct 9.


The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.

Henchoz-Lecoanet S, Jeannin P, Aubry JP, Graber P, Bradshaw CG, Pochon S, Bonnefoy JY.

Immunology. 1996 May;88(1):35-9.


Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.

Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W.

EMBO J. 1991 Apr;10(4):919-26.


Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.

Hannan JP, Young KA, Guthridge JM, Asokan R, Szakonyi G, Chen XS, Holers VM.

J Mol Biol. 2005 Feb 25;346(3):845-58. Epub 2005 Jan 8.


Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).

Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM.

Mol Immunol. 2013 Jan;53(1-2):99-110. doi: 10.1016/j.molimm.2012.07.002. Epub 2012 Aug 10.


Structure of complement receptor 2 in complex with its C3d ligand.

Szakonyi G, Guthridge JM, Li D, Young K, Holers VM, Chen XS.

Science. 2001 Jun 1;292(5522):1725-8.


Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation.

Holers VM, Kulik L.

Mol Immunol. 2007 Jan;44(1-3):64-72. Epub 2006 Jul 28. Review.


Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP.

J Virol. 2008 Nov;82(22):11217-27. doi: 10.1128/JVI.01673-08. Epub 2008 Sep 10.


Structure of complement receptor (CR) 2 and CR2-C3d complexes.

Hannan J, Young K, Szakonyi G, Overduin MJ, Perkins SJ, Chen X, Holers VM.

Biochem Soc Trans. 2002 Nov;30(Pt 6):983-9. Review.


CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21.

Aubry JP, Pochon S, Gauchat JF, Nueda-Marin A, Holers VM, Graber P, Siegfried C, Bonnefoy JY.

J Immunol. 1994 Jun 15;152(12):5806-13.


Supplemental Content

Support Center